CIRM - California Institute for Regenerative Medicine
07/17/2024 | News release | Distributed by Public on 07/17/2024 10:03
$53 million awarded to fund clinical and translational research
[Link]
The California Institute for Regenerative Medicine (CIRM) recently awarded $53 million to fund various projects, from its Clinical and Translational programs aimed at preventing heart failure to the advancement of cell therapy for Parkinson's disease and the targeting of numerous cancers.
Two preclinical projects are providing funding for eligible stem cell and gene therapy-based projects at all stages of clinical trial development.
The goal of CIRM's Translational program is to support promising stem cell-based or gene projects that accelerate the completion of translational stage activities necessary for advancement to clinical study or broad-end use. Those can include therapeutic candidates, diagnostic methods or devices, and novel tools that address critical bottlenecks in research.
The successful applicants in CIRM's Translational program for May 2024 are:
| Application # | Program Title | Principal Investigator/Institution | Amount |
| TRAN1-16050 | Combating Ovarian Cancer with Stem Cell-Engineered Off The-Shelf CAR-NKT Cell Therapy | Yang, Lili - UCLA | $6,312,000 |
| TRAN1-16225 | Development of a universal allogeneic human interneuron cell therapy candidate for the treatment of drug resistant focal epilepsy | Nicholas, Cory R. - Neurona Therapeutics | $3,828,714 |
| TRAN1-16011 | Development of a Gene Therapy for Treatment of Guanidinoacetate Methyltransferase Deficiency-Translating In Vivo Proof of Concept to Support a Pre-IND | Lipshutz, Gerald - UCLA | $5,145,825 |
| TRAN1-16026 | Toward a Cure for Gaucher Disease Type 1: Autologous Transplantation of Genome Edited Hematopoietic Stem Cells | Gomez-Ospina, Natalia - Stanford | $4,997,237 |
| TRAN2-16061 | A Rapid Clinical Digital Patient-derived Organoid to Guide Breast Cancer Treatment Decision | Yuan, Yuan - Cedars-Sinai | $1,535,375 |
| TRAN1-16023 | Hypoimmunogenic iPSC-derived TCR-NK cells for oncology | Conway, Anthony - Replay Holdings, Inc. | $4,107,571 |
| TRAN1-16012 | A high quality, accessible cell therapy for Parkinson's Disease produced in a scalable bioreactor system for 3D cell expansion and differentiation | Joshi, Abhay - Axent Biosciences Inc. | $3,999,241 |
| TRAN1-16013 | Development of an UNC13A Targeting Antisense Oligonucleotide (ASO) Treatment for ALS, for IND-enabling Studies | Alworth, Samuel V. - AcuraStem Inc. | $4,012,325 |
| TRAN1-16192 | Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells | Tian, Lei - Beckman Research Institute of City of Hope | $6,036,000 |
| TRAN4-16091 | Purification of Human Hematopoietic Stem Cells (HSCs) for Clinical Stem Cell Transplantation | Weissman, Irving L. - Stanford | $1,499,683 |
To learn more about CIRM's translational funding program, visit this page on our website. To learn more about these awards, explore our grants database on our website.